TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25201934
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy‐oriented anger management and stress control program
Study: 20029974
Drug: Celiac axis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiac axis infusion chemotherapy combined with radiotherapy (CAI/RT)
Study: 1316401
Drug: Low-sodium diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-sodium diet (LSD) with lactose capsules
Study: 1316401
Drug: Normal-sodium diet
Normalized name: sulfacetamide sodium Medicated Pad [Rosula NS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-sodium diet (NSD) with salt capsules
Study: 29888656
Drug: Lactobacillus acidophilus
Normalized name: Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2, 2 capsules daily containing 50×10^9 cfu of live organisms
Study: 29888656
Drug: Placebo, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 2 capsules daily
Study: 21427425
Drug: Continuous therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous therapy (CT, n = 65)
Study: 9562293
Drug: C (caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: C (caffeine 5 mg x kg[-1])
Study: 9562293
Drug: E (ephedrine
Normalized name: Primatene (ephedrine hydrochloride 12.5 MG / guaifenesin 200 MG) Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: E (ephedrine 1 mg x kg[-1])
Study: 9562293
Drug: C+E (caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: C+E (caffeine and ephedrine combination)
Study: 7936513
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate 10 mg/day for 14 days every 28 days
Study: 7936513
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate 10 mg/day for 28 of 84 days
Study: 7936513
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate 10 mg/day for 14 days every 84 days
Study: 7936513
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (less than monthly)
Study: 7936513
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (monthly)
Study: 2447257
Drug: Early high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early high-dose phenobarbital treatment (15 mg/kg IV at 110 minutes, followed by 15 mg/kg after 4 hours, then 5 mg/kg every 24 hours for 5 days)
Study: 2447257
Drug: Early high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early high-dose phenobarbital treatment
Study: 26337539
Drug: Bi-weekly alternating
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bi-weekly alternating ranibizumab/bevacizumab injections
Study: 21138462
Drug: Testosterone supplementation
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone supplementation (160 mg/day of oral testosterone undecanoate)
Study: 15760313
Drug: Buscopan suppositories
Normalized name: Buscopan
DrugBank: Butylscopolamine (DB09300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buscopan suppositories
Study: 9845395
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg (ulcer-like dyspepsia)
Study: 9845395
Drug: Omeprazole 10
Normalized name: omeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 10 mg (ulcer-like dyspepsia)
Study: 9845395
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg (reflux-like dyspepsia)
Study: 9845395
Drug: Omeprazole 10
Normalized name: omeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 10 mg (reflux-like dyspepsia)
Study: 7814301
Drug: Nilvadipine (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilvadipine (16 mg daily)
Study: 29526614
Drug: Elosulfase alfa
Normalized name: Elosulfase alfa
DrugBank: Elosulfase alfa (DB09051)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Elosulfase alfa 2.0 mg/kg/week
Study: 15994264
Drug: Cisplatin-based chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based chemotherapy + supportive care (C)
Study: 10093002
Drug: CR2194 (spiroglumide)
Normalized name: proglumide
DrugBank: Proglumide (DB13431)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR2194 (spiroglumide) 1, 2.5 or 7.5 mg kg‐1 h‐1
Study: 10093002
Drug: CR2194 (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR2194 (7.5 mg kg‐1 h‐1)
Study: 8604591
Drug: desferrioxamine B
Normalized name: Deferrioxamine B
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: desferrioxamine B (100 mg/kg/day) as a single agent
Study: 8604591
Drug: desferrioxamine B
Normalized name: Deferrioxamine B
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: desferrioxamine B in addition to standard quinine-based therapy
Study: 8604591
Drug: placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo in addition to standard quinine-based therapy
Study: 22896665
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg BMS‐663068 plus 100 mg ritonavir every 12 hours (Q12H)
Study: 22896665
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg BMS‐663068 plus 100 mg ritonavir every bedtime
Study: 22896665
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg BMS‐663068 plus 100 mg ritonavir Q12H
Study: 22896665
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg BMS‐663068 Q12H plus 100 mg ritonavir every morning
Study: 22896665
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg BMS‐663068 Q12H
Study: 12379064
Drug: Ximelagatran, 24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran, 24 mg twice daily for 7 to 12 days
Study: 12379064
Drug: Warfarin (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (target INR 2.5, range 1.8 to 3.0), starting on the evening of the day of surgery
Study: 9822045
Drug: Moxonidine (0.2-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine (0.2- to 0.4-mg)
Study: 9822045
Drug: Cilazapril (2.5-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril (2.5- to 5.0-mg)
Study: 8017470
Drug: Fluvastatin 20
Normalized name: fluvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 20 mg once daily for 6 weeks, then 20 mg twice daily for an additional 6 weeks
Study: 2637069
Drug: Pentazocin or
Normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentazocin or Piritramid (analgesics)
Study: 334185
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg of aspirin
Study: 334185
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of 43‐715 (1‐isopropyl‐4‐phenyl-7-methyl-2 (1H) quinazolone)
Study: 334185
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of 43‐715 (1‐isopropyl‐4‐phenyl-7-methyl-2 (1H) quinazolone)
Study: 334185
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of 43‐715 (1‐isopropyl‐4‐phenyl-7-methyl-2 (1H) quinazolone)
Study: 31555976
Drug: Nutraceutical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutraceutical treatment (Omega‐3: EPA 1 g/DHA 656 mg, SAMe, zinc, 5‐HTP, folinic acid, and co‐factors)
Study: 25705872
Drug: 52 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 52 weeks nicotine patch treatment
Study: 23518148
Drug: Sunitinib therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib therapy (2nd-line)
Study: 21460008
Drug: Pentavalent antimony
Normalized name: Pentavalent Antimony
DrugBank: Pentavalent Antimony (DB13047)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentavalent antimony treatment with early antihelminthic therapy
Study: 21460008
Drug: Pentavalent antimony
Normalized name: Pentavalent Antimony
DrugBank: Pentavalent Antimony (DB13047)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentavalent antimony treatment with deferred antihelminthic therapy
Study: 16469323
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogen (CEE) therapy
Study: 9182082
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil tablet form (250 mg)
Study: 9182082
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil granule form (250 mg)
Study: 2967185
Drug: Bisoprolol 10
Normalized name: bisoprolol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 10 mg o.d. for 4 weeks, then 20 mg o.d. for 4 weeks
Study: 2967185
Drug: Verapamil 80
Normalized name: verapamil 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 80 mg t.i.d. for 4 weeks, then 120 mg t.i.d. for 4 weeks
Study: 30309721
Drug: IV elesclomol
Normalized name: Elesclomol
DrugBank: Elesclomol (DB05719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV elesclomol plus weekly paclitaxel
Study: 24769437
Drug: D-cycloserine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-cycloserine (50 mg) each treatment day
Study: 24769437
Drug: Greater distribution
Normalized name: greater celandine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Greater distribution of treatment (10 weeks)
Study: 17640375
Drug: Sucrose (44%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (44% sucrose, 2 ml)
Study: 17640375
Drug: Control (sterile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (sterile water, 2 ml)
Study: 12932114
Drug: Tc-99m DTPA
Normalized name: TECHNETIUM (Tc 99m)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tc-99m DTPA radioaerosol lung scintigraphy (inhalation of radiotracer for 5 minutes)
Study: 8664521
Drug: CyA and
Normalized name: CyA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CyA and steroids (group 1)
Study: 6401365
Drug: D-penicillamine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-penicillamine therapy for 1 year
Study: 6401365
Drug: Oral gold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral gold (Auranofin)
Study: 31924332
Drug: T +
Normalized name: RE PreVit + DHA Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: T + PLD (trabectedin 1.1 mg/m2 for 3 h; PLD 30 mg/m2 for 1.5 h, every 3 weeks)
Study: 31924332
Drug: PLD (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLD (50 mg/m2 for 1.5 h, every 4 weeks)
Study: 24880643
Drug: Ivermectin (IVM)
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin (IVM) at 0.2 mg/kg bodyweight
Study: 24880643
Drug: Moxidectin (MOX)
DrugBank: Moxidectin (DB11431)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxidectin (MOX) at 0.4 mg/kg bodyweight
Study: 16358301
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) at a dose of 1,000 mg/m2 given as a 36-hour continuous infusion
Study: 9521199
Drug: Double therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double therapy (CsA [10 mg/kg/day] plus prednisone)
Study: 9521199
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (CsA [6 mg/kg/day] plus azathioprine plus prednisone)
Study: 8004841
Drug: Bisoprolol (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (all doses combined)
Study: 788293
Drug: Flutamide (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (high or low dose)
Study: 788293
Drug: Diethylstilbestrol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diethylstilbestrol (1 mg daily)
Study: 29444502
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 1% starch and 10% sucrose
Study: 23893098
Drug: Project SEARCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Project SEARCH plus ASD Supports (treatment group)
Study: 22399630
Drug: Carboplatin (AUC5)
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin (AUC5) on day 1 with escalating oral topotecan (3.0 mg/m² starting dose) on days 1, 8, and 15, every 4 weeks
Study: 22399630
Drug: Carboplatin (AUC5)
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin (AUC5) with oral topotecan
Study: 20592644
Drug: Therapeutic drug
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic drug monitoring (TDM) for adjusting doses of HIV-1 protease inhibitors (PIs)
Study: 15913800
Drug: 4-week ribavirin
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week ribavirin (RIB) administration followed by 24-week combination treatment with interferon (IFN) and RIB (Group A)
Study: 15913800
Drug: 24-week combination
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 24-week combination treatment with interferon (IFN) and ribavirin (RIB) only (Group B)
Study: 12806908
Drug: Logotherapy (added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Logotherapy (added to loxoprofen sodium treatment)
Study: 26853244
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy, noise cancelling earplugs, and eye mask
Study: 17372126
Drug: Risedronate (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (2.5 mg daily) and vitamin D2 (1,000 IU)
Study: 6168848
Drug: Mexiletine (600-1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine (600-1000 mg/day)
Study: 25388643
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection hyaluronic acid (IAHA) for 4 weeks
Study: 25388643
Drug: Oral glucosamine
Normalized name: glucosamine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucosamine sulfate (GS) for 12 weeks
Study: 25388643
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection hyaluronic acid (IAHA)
Study: 25064093
Drug: Multidisciplinary rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary rehabilitation programme (motor training and cognitive-behavioural therapy)
Study: 17662095
Drug: All agents
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All agents (group 1, group 2, group 3)
Study: 15787921
Drug: levobupivacaine 0.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: levobupivacaine 0.2% (1 ml x kg(‐1))
Study: 15787921
Drug: ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine 0.2% (1 ml x kg(‐1))
Study: 15787921
Drug: bupivacaine 0.2%
Normalized name: BUPivacaine 0.2%-NaCl 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 0.2% (1 ml x kg(‐1))
Study: 11923128
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy with sequential paclitaxel and doxorubicin-based combination chemotherapy
Study: 3524419
Drug: Ceftazidime 4
Normalized name: CEFTAZIDIME 40ML/ML INJ,50ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 4 g per day for 26 to 63 days (mean, 45 days)
Study: 16229991
Drug: Sequential intravenous/oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential intravenous/oral moxifloxacin (400 mg once a day)
Study: 16229991
Drug: Intravenous piperacillin-tazobactam
Normalized name: piperacillin / tazobactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous piperacillin-tazobactam (3.0/0.375 g every 6 h) followed by oral amoxicillin-clavulanate (800 mg every 12 h)
Study: 16229991
Drug: Intravenous piperacillin-tazobactam
Normalized name: piperacillin / tazobactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate
Study: 8522666
Drug: Urinastatin (100,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinastatin (100,000 U dose immediately after arrival, followed by three 100,000 U doses at 8-hour intervals within the first 24 hours)
Study: 22706336
Drug: Latanoprost 0.005%
Normalized name: LATANOPROST 0.005% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost 0.005% once daily (1 drop PM)
Study: 22706336
Drug: Timolol 0.5%
Normalized name: Timolol 0.5% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 0.5% twice daily (1 drop AM and PM)
Study: 15476485
Drug: Anti-CD25 monoclonal
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-CD25 monoclonal antibody (anti-CD25 mAb) administered to high immunological risk patients
Study: 9766411
Drug: Nebulized furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized furosemide 1 mg/kg
Study: 9766411
Drug: Nebulized furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized furosemide 2 mg/kg
Study: 337094
Drug: Continue antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue antibiotics (CCG + chloramphenicol or clindamycin)
Study: 337094
Drug: Stop antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stop antibiotics
Study: 26324740
Drug: lenvatinib 24
Normalized name: lenvatinib 24 MG Daily Dose 30 Day Supply Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: lenvatinib 24 mg orally per day (n = 261)
Study: 26324740
Drug: lenvatinib 24
Normalized name: lenvatinib 24 MG Daily Dose 30 Day Supply Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: lenvatinib 24 mg orally per day
Study: 21860340
Drug: Buprenorphine (BUP)
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine (BUP) sublingual tablet (14-20 mg)
Study: 19626663
Drug: INGAP peptide
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: INGAP peptide 600 mg/day
Study: 19626663
Drug: INGAP peptide
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: INGAP peptide 300 mg/day
Study: 17377106
Drug: Ketamine (intraoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (intraoperative 0.3 mg/kg and postoperative infusion at 0.1 mg x kg(‐1) x h(‐1))
Study: 10434906
Drug: PSA level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA level over 20 ng ml‐1
Study: 10434906
Drug: PSA level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA level below 20 ng ml‐1 and Gleason score below 6
Study: 21478817
Drug: CNI therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNI therapy
Study: 19252046
Drug: Interpersonal psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal psychotherapy for 12 weekly sessions followed by two monthly booster sessions
Study: 16988200
Drug: 100-mg 2-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-mg 2-hour intravenous infusion
Study: 16988200
Drug: 200-mg oral
Normalized name: lesinurad
DrugBank: Lesinurad (DB11560)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 200-mg oral administration twice daily
Study: 16988200
Drug: 200-mg/d continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200-mg/d continuous intravenous infusion
Study: 15163481
Drug: Trivalent, intranasal,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent, intranasal, live attenuated influenza virus vaccine
Study: 10912948
Drug: Gemcitabine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (200 mg/m2, with possible escalation to 250 mg/m2), administered as a 360 min infusion on days 1, 8, and 15 of a 28-day cycle.
Study: 9487432
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (corticosteroid)
Study: 30650322
Drug: Tafenoquine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine (300 mg single dose)
Study: 30650322
Drug: Primaquine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine (15 mg once daily for 14 days)
Study: 24523332
Drug: Recombinant erythropoietin
Normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant erythropoietin (Eprex) administered hypodermically 10,000 units 3 times a week during 6 months
Study: 9821025
Drug: Intravenous low
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous low molecular weight heparin (LMWH)
Study: 9821025
Drug: Subcutaneous low
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous low molecular weight heparin (LMWH)
Study: 8605054
Drug: Aerosolized pentamidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized pentamidine (AP; 300 mg monthly)
Study: 8605054
Drug: Cotrimoxazole (CTX;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotrimoxazole (CTX; 160 mg trimethoprim and 800 mg sulfamethoxazole every other day)
Study: 8605054
Drug: Dapsone-pyrimethamine (DP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone-pyrimethamine (DP; 100 mg weekly dapsone and 25 mg biweekly pyrimethamine)